Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)
ConditionAcute Ischemic Stroke
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorStemCyte, Inc.
About this trial
A Phase II, Randomized, Double-blind, Parallel, Placebo-controlled Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke
Eligibility criteria
Qualifiers
Male or female subject ≥18 and ≤80 years of age.
Subject with a confirmed diagnosis of AIS and hemiplegia
Disqualifiers
Subject with known immune disease, immunodeficiency, or receives immunosuppressive therapy/immunomodulators within 4 weeks or 5 half-lives prior to screening, whichever is longer.
Trial design
Treatments tested in this trial
- hUCB
Treatment groups
39 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
StemCyte, Inc.
Lead sponsor
StemCyte Taiwan Co., Ltd.
Collaborator
Source ClinicalTrials.gov